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Obesity is increasing in prevalence throughout the world(see the report by Group I), and with this change, there
is a major increase in associated cardiac, metabolic, and other
noncommunicable diseases.1 This increase is particularly
noticeable in countries in which there has not previously been
an overweight and obesity problem, but it is also evident in
countries in which obesity has been present for decades.
Although in the past, obesity had some positive societal
implications, representing wealth, fertility, and power, in the
later decades of the 20th century and now in the 21st century,
the perception of overweight and obesity has changed in
developed society and also has changed in most other
societies. Obesity (the definitions of overweight and obesity
are given in the 2000 World Health Organization [WHO]
Technical Report2 and elsewhere in this report) now is seen as
a social hindrance and is known to be associated with disease.
Visceral or intraabdominal obesity, in contrast to subcutane-
ous or lower-body obesity, carries the greatest risk of cardiac
and metabolic diseases. However, we must still recognize that
overweight and obesity are part of a continuum and that
health risks increase with increasing weight in the individual.
Associated Diseases and Disorders
Mortality
The mortality associated with excess weight increases as the
degree of obesity and overweight increases. One study
estimated that between 280 000 and 325 000 deaths annually
in the United States could be attributed to obesity.3 More than
80% of these deaths occur among people with a body mass
index (BMI) 30 kg/m2. The increase in death from obesity
has been documented in a number of studies from around the
world (Table 1).
In the Nurses’ Health Study,4 the risk of death in women
with a BMI 19 kg/m2 rose progressively. Mortality was
lowest among women who weighed at least 15% less than the
US average for women of similar age and among those whose
weight had been stable since early adulthood. The American
Cancer Society’s Prevention Study I has shown that among
62 116 white men and 262 019 white women (both groups
were healthy nonsmokers and were followed up for 14 years),
a greater BMI was associated with increased death rate from
all causes and from cardiovascular disease in both groups up
to age 75. The impact of the excess body weight was higher
among younger subjects than it was among older ones.5 In an
even larger study (457 785 men and 588 369 women) with a
14-year follow-up (American Cancer Society’s Prevention
Study II), the association of BMI and mortality was affected
by smoking status and history of other disease. Among the
nonsmokers, the lowest mortality for men was in the BMI
group 23.5 to 24.9 kg/m2 and for women it was in the BMI
group 22.0 to 23.4 kg/m2. Among subjects with a BMI 40
kg/m2, the relative risk of death was 2.6 times higher for men
and 2.0 times higher for women compared with those who
had a BMI between 23.5 and 24.9 kg/m2. Black men and
women had lower risks than corresponding categories of
whites. No effect of age existed, and the risk of death or
cardiovascular disease did not significantly increase over the
BMI range 22.0 to 26.4 kg/m2 for men and 20.5 to 24.9 kg/m2
for women.6 In the Aerobics Center Longitudinal Study,
25 714 men were observed for up to 10 years. The all-cause
and cardiovascular mortalities were higher in men with a
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BMI 30 kg/m2 and lowest in men with a BMI 18.5 to 24.9
kg/m2. Men with a BMI of 25 to 29.9 kg/m2 had a mortality
falling in between.7 The deaths from cardiovascular disease
increased from a little more than 5 deaths/10 000 man-years
with a body fat of 16.7% to nearly 8 deaths/10 000
man-years in men with a body fat of 16.7% to 25.0% and to
nearly 12 deaths/10 000 man-years in men with a body fat
25.0%. The association between obesity and the risk of
death from coronary heart disease (CHD) was confirmed by
a study of 8373 Finnish women (aged 30 to 59 years)
observed for 15 years.8 This study found that for each
increase of 1 kg in body weight, the risk of coronary
mortality increased by 1% to 1.5%. A substantial part of this
risk was mediated through the link between body weight and
blood pressure.
Cardiovascular Disease
Foremost in the global burden of cardiovascular diseases are
CHD and stroke. The Global Burden of Disease Study ranked
these conditions first and second among all categories of
death in worldwide mortality for 1990.12 The same study
projected that by 2020 these conditions would persist in the
first and second ranks among causes of death. They also were
predicted to hold first and fourth ranks in terms of disability-
adjusted years of life lost (an index that takes into account age
at death and years of disability for survivors with these
conditions). Closely related clinically but not separately
analyzed is heart failure due to atherosclerosis and hyperten-
sion. Heart failure doubtless adds considerably to the burden
of cardiovascular diseases throughout the world. However,
estimation of this component of heart disease is not reliable
because of even more limited data and is further complicated
by the major contributions of other conditions, such as
rheumatic heart disease, Chagas disease, and cardiomyopa-
thies, to the burden of heart failure in many countries.13
The World Heart Federation has compiled extensive data
on the burden of cardiovascular diseases in major geopolitical
regions of the world (information available at www.world-
heart.org).14 By 1996, the proportion of deaths attributable to
circulatory conditions already was estimated to be 29.0%
worldwide, 45.6% in developed countries, and 24.5% in
developing countries; the latter increased from 16%—or by
one half—as estimated by the WHO in 1980.15 The corre-
sponding increases from 1990 to 2010 in the industrial market
economies, economies in transition, and developing countries
were projected to be 1.8%, 19.4%, and 28.2%, respectively.14
Thus, the global burden of these cardiovascular conditions is
great and growing.
Variation among countries in the occurrence of these
conditions was first investigated systematically in the Seven
Countries Study, beginning in the late 1950s and 1960s.16 A
10-fold range in incidence of CHD was found in the Seven
Countries Study among 16 cohorts of middle-aged men in
Europe, Japan, and the United States. These differences were
explained primarily by differences in dietary fat consumption,
blood cholesterol concentration, and blood pressure among
the cohorts and not by differences in BMI. This finding was
possibly the result of the narrow range and mainly “normal”
mean values of BMI at baseline among the cohorts.17 In
addition, because of the prior wartime dietary conditions of
most of these populations at the time of baseline examina-
tions, the BMI may have measured relatively more lean mass
and less fat mass than would be the case for today’s
populations in the same areas.
A similarly wide range of incidence and mortality rates
from CHD was shown in the WHO MONICA Project,
conducted from the mid-1980s through mid-1990s in 31
countries.18 The majority of study populations were from
Europe, although populations from Australia, China, New
Zealand, and the United States were included. Ten-year
trends in fatal and nonfatal CHD events were compared with
trends in BMI as measured in population samples in the same
study areas. The results depended on inclusion or exclusion of
anomalous findings from 5 populations in the Common-
wealth of Independent States that experienced a decline in
TABLE 1. All-Cause and Disease-Specific Cause of Death
From Several Epidemiological Studies in Relation to Body
Mass Index
All-Cause Mortality*
Study and BMI Criteria, kg/m2 Male Female
Nurses Health Study9
(age 30–55 y, with 16 years’ follow-up)
19.0–21.9    2.46
22.0–24.9    2.46
25.0–26.9    2.61
27–28.9 3.35
29–31.9    3.90
32    4.64
British Regional Heart Study10
(age 40–59 y, with 13.8 years’ follow-up)
20–21.9 12.6   
22–23.9 11.5   
24–25.9 11.8   
26–27.9 11.8   
28–29.9 13.3   
30 16.8   
Gothenberg Birth Cohort11
(age 47–55 y, with 19.7 years’ follow-up)
20.0–22.5 15.5   
22.5–25.0 13.9   
25.0–27.5 14.3   
27.5–30 16.6   
30 21.1   
Cancer Prevention Study II (age 65–74 y)6
22.0–23.4 8.54 4.98
23.5–24.9 8.98 5.95
25.0–26.4 9.41 5.98
26.5–27.9 10.38 6.36
28.0–29.9 12.70 7.96
30.0–31.9 13.70 8.36
32.0–34.9 17.98 11.11
35.0 27.67 12.99
*Deaths/1000 patient-years.
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BMI. Only after exclusion of these populations from analysis
did change in BMI contribute importantly to the observed
trends in coronary event rates, explaining 31% and 10% for
men and women, respectively, of the observed variation in
trends in event rates.
On a population-wide basis, the contribution of the contin-
uously graded distribution of BMI to the pandemic occur-
rence of CHD and stroke appears to have two essential
aspects. First is the relation of BMI to mortality independent
of the major risk factors, including blood cholesterol concen-
tration, blood pressure, and smoking. Second is the more
immediate relation of BMI to the risk factors themselves.
These two aspects are illustrated by data from Finland, based
on a 15-year follow-up of more than 13 000 men and women
aged 30 to 59 at examination in 1972 or 1977 in North
Karelia.8 Throughout the distribution of baseline values of
BMI, CHD death rates increased for men; for women, rates
increased from 18.5 kg/m2 to 20 to 31.9 kg/m2 and
increased further for those at or 32 kg/m2.
The regression coefficients for BMI and CHD mortality for
both men and women were evaluated by adjustment for major
risk factors (eg, smoking, total cholesterol concentration,
systolic blood pressure) separately and together. The results
indicated that the BMI–coronary mortality relationship was
influenced by all three factors. Consistent with extensive data
from other sources, BMI was associated directly with both
blood lipids and blood pressure and inversely with smoking.
In addition, significant relationships between BMI and coro-
nary mortality persisted after this adjustment for both men
and women. Subjects with diabetes at baseline for this study
were excluded; however, new-onset diabetes may have had
an influence on risk estimates.8 Overall, BMI appears to
contribute to the development of other major risk factors (eg,
blood lipids, blood pressure) and independently to CHD
mortality.
As the prevalence of overweight has increased in pediatric
age groups, so has the frequency of diagnosis of the compli-
cations of obesity that typically have been seen in the adult
population. Risk factors for the development of coronary
artery disease coexist in obese adolescents.19 Hyperlipidemia,
hyperinsulinemia, and early atherosclerosis are seen more
commonly among obese adolescents than they are in normal
weight cohorts. In the Bogalusa Heart Study nearly 60% of
obese children had 1 risk factor for cardiovascular disease
and 20% had 2 or more risk factors.20
Although only limited data are available to estimate the
contribution of obesity, as measured by BMI or other indices,
to the risk of stroke, the role of obesity in the development of
blood lipids and blood pressure argues for an important
contribution to the risk of stroke, especially hemorrhagic
stroke.13
The following conclusions can be stated about cardiovas-
cular disease:
● Atherosclerotic and hypertensive cardiovascular disorders,
especially CHD and stroke, are pandemic in their global
occurrence, which is projected to increase dramatically in
the next 2 decades, and constitute the leading cause of
death and disability in the world population.
● The underlying risk factors are equally widespread and
reflect demographic, economic, and social changes that
result from local, national, regional, and global influences
on multiple sectors of society.
● The prevalence of obesity, defined as a BMI of 30 kg/m2,
is increasing rapidly in many populations throughout the
world, among both children and adults, with varying rates
of increase in specific groups. Underlying this phenomenon
is a longstanding, widespread shift in the population
distribution of BMI, as documented for the United States in
birth cohorts from the late 19th to the late 20th centuries.15
● The contribution of obesity to risk of cardiovascular
diseases, partly through the development of other major
risk factors and partly through direct effects on CHD and
possibly on stroke, is a major reason for concern about the
rising frequency of obesity.
● Obesity and its consequences are in principle preventable.
In this era of its high and growing prevalence, the preven-
tion of obesity is a necessary component of strategies to
prevent not only heart disease and stroke but their major
risk factors as well.
Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is strongly associated with
obesity in all ethnic groups. More than 80% of cases of
T2DM can be attributed to obesity, which also may account
for many diabetes-related deaths. Projections by the WHO
show an alarming rate of increase in the prevalence of
diabetes over the next decade. As can be easily seen in Table
2, important regional differences are found in the rate of
increase. At the low end are North America, Europe, and
Australia. Asia is the area with the greatest growth rate,
making it the area in which preventive strategies are the most
important.
The risk of T2DM increases with the degree and duration
of obesity and with central distribution of body fat. A study of
51 000 male health professionals in the United States22 found
a strong positive association between overall obesity (mea-
sured by BMI) and the risk of diabetes. The relative risk for
diabetes in men with a BMI of 35 kg/m2 was 40 times higher
than that for men with a BMI of 23 kg/m2. A similarly strong
curvilinear relationship between BMI and the risk of T2DM
was found in women.23 The lowest risk was associated with
a BMI 22 kg/m2, and at a BMI 35 kg/m2 the relative risk
for diabetes adjusted for age increased to 61 kg/m2. The risk
TABLE 2. Estimates of Regional Prevalence of Diabetes in
2000 and 2010 in Millions of Cases
Region 2000 2010 Increase, %
North America 14.2 17.5 23
Europe 26.5 32.0 24
Australia 1.0 1.3 33
South America 15.6 22.5 44
Africa 9.4 14.1 50
Asia 84.5 132.3 57
World average 151 221 46
Data from Zimmet et al, 2001.21
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may be further increased by a sedentary lifestyle or decreased
by exercise. Weight gain after age 18 in women and after age
20 in men also increases the risk of T2DM. Weight gain
precedes the onset of diabetes. Among Pima Indians (a group
with a particularly high incidence of T2DM), for example,
body weight gradually increased 30 kg (from 60 kg to 90 kg)
in the years preceding the diagnosis of diabetes.24 After the
diagnosis of diabetes, a small decrease in body weight
occurred. In long-term follow-up studies there was also a
strong relationship between the duration of obesity and the
change in plasma glucose concentrations during an oral
glucose tolerance test.
Conversely, weight loss is associated with a decreased risk
of T2DM. In the Swedish Obesity Study diabetes was present
in 13% to 16% of obese subjects at baseline.25 Among those
who underwent gastric bypass and subsequently lost weight,
69% with diabetes were cured, and only 0.5% of those who
did not have diabetes at baseline developed the disorder. In
comparison, obese subjects who did not lose weight had a
higher incidence of T2DM (7.8%). Individuals with impaired
glucose tolerance participating in the Diabetes Prevention
Program (DPP) involving a lifestyle modification program,
which included 150 min/wk of exercise and a weight loss of
7% body weight, had a 58% reduction in the progression to
diabetes.26 The risk reduction associated with the lifestyle
intervention in the DPP study was the same as that in a
smaller trial conducted in Finland,27 and was higher than the
reductions associated with diet (31%), exercise (46%), and
diet plus exercise (42%) in a study in China.28
Insulin Resistance
Insulin resistance with hyperinsulinemia is characteristic of
obesity and is present before the onset of hyperglycemia.
With obesity early demonstrable changes are alterations of
insulin-mediated antilipolysis, impairment in glucose re-
moval, and increased insulin resistance, which result in
hyperinsulinemia. This hyperinsulinemia is associated with
increases of hepatic very-low-density triglyceride synthesis
(VLDL triglyceride), plasminogen activator inhibitor-1 syn-
thesis, sympathetic nervous system activity, and sodium
reabsorption. These changes contribute to dyslipidemia and
hypertension in subjects who are obese. The insulin resistance
characteristic of T2DM probably results from a combination
of obesity and genetic factors. In a study of nondiabetic
offspring of two parents with T2DM insulin sensitivity was
similar to that of normal subjects (with no first-degree
relatives with T2DM and at near ideal body weight). With
increasing degrees of obesity a progressive decrease in
insulin sensitivity was much more pronounced in those with
a family history of T2DM.29 The mechanism by which
obesity induces insulin resistance is poorly understood. Many
factors may be important and interactive, including free fatty
acids (FFA), tumor necrosis factor-alpha (TNF-), the pattern
of fat distribution, and multiple genetic abnormalities.
Liver Disease
Nonalcoholic fatty liver disease (NAFLD) has become rec-
ognized as one of the most common abnormalities observed
in obese individuals. NAFLD refers to a wide spectrum of
liver disease. Classically, suspicion of NAFLD is raised by an
elevation of serum transaminases in the absence of excessive
alcohol intake, negative serology for viral hepatitis, no
autoimmune disease, and the lack of other known causes of
liver disease. Imaging studies are consistent with steatosis.
When performed, the liver biopsy shows steatosis, inflamma-
tory cell infiltration with portal predominance often surround-
ing ballooned hepatocytes, and fibrosis that will eventually
progress to severe cirrhosis. Nonalcoholic steatohepatitis
(NASH), a term used in earlier reports of liver disease
associated with obesity, represents only one stage within the
spectrum of NAFLD.30–32 It is not clear why simple steatosis
develops only in some individuals, whereas others progress to
severe cirrhosis. It has been estimated that severe fibrosis
occurs in up to 50% of obese individuals and cirrhosis
develops in 7% to 16%.33–35 Dyslipidemia and insulin resis-
tance both are strongly associated with the presence of
NAFLD, and limited data suggests that a correlation may
exist between the severity of the metabolic disorder and the
severity of liver disease.30
Analysis of the National Health and Nutrition Examination
Survey III (data collected from 1988 to 1994) used criteria for
NAFLD diagnosis of the presence of 1 or more elevated liver
enzyme value with no alternative explanation. The prevalence
of NAFLD increased with increasing BMI and increased with
increasing waist circumference, and men had a greater like-
lihood of NAFLD than women at all ages.30 Overall, NAFLD
has been reported to affect 10% to 24% of populations of
various countries and up to 74% of obese individuals.31
Weight loss often has showed improvement in the under-
lying liver disease, although with rapid weight loss there have
been observations of worsening of the histological findings.31
The most effective rate of weight loss awaits further study.
No documented pharmacological treatment has been shown
to be effective, although good medical management of
glucose levels and lipid levels should be encouraged.
Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a disease associated with
obesity that is characterized by loud snoring and repetitive
closure (apnea) or partial closure (hypopnea) of the upper
airway during sleep. The increasing respiratory efforts to
overcome airway closure lead to arousals from sleep and
fragmentation of normal sleep patterns. The major daytime
complaint is excessive daytime sleepiness (EDS) that results
from disturbed sleep. About 25% of middle-aged men and 9%
of middle-aged women have OSA36,37 (defined categorically
as an apnea-hypopnea index [AHI] 5). OSA with signifi-
cant EDS occurs in about 2% and 4% of middle-aged women
and men, respectively.37
Actual apneic events are associated with increased blood
pressure, cardiac arrhythmia, and increased muscle sympa-
thetic nerve activity.38 When awake, patients with OSA have
increased muscle sympathetic nerve activity, even adjusting
for the effects of obesity.38 Evidence is increasing that OSA
is a risk factor for the development of hypertension, ischemic
heart disease, congestive heart failure, stroke, and conse-
quently, premature death.38,39 Even patients with mild degrees
of OSA are at a much greater risk of developing hypertension
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than those without after adjusting for all major known risk
factors.40 Moreover, a very high prevalence of OSA in
drug-resistant hypertension has been observed.38 Insulin re-
sistance also is associated with OSA independent of obesity.41
More recent studies show that OSA is associated with higher
levels of various atherogenic mediators. Treatment of OSA
can reduce the levels of these mediators. There is also recent
randomized clinical trial data showing that blood pressure is
reduced by medium-term treatment of OSA with nasal
continuous positive airway pressure.42
All epidemiological investigations have shown consis-
tently that obesity, especially central obesity, is strongly
associated with OSA36,37,43 Conversely, OSA is overrepre-
sented in obese subjects.43 It has been suggested that a
considerable part of the excess morbidity in the obese
population is mediated by OSA.43 Weight loss can reduce
OSA severity,44 but controlled or long-term data are limited.
Musculoskeletal Disorders
The incidence of osteoarthritis is increased in obese subjects
and accounts for a major component of the cost of obesity.45
Osteoarthritis commonly develops in the knees and ankles;
this may be directly related to the trauma associated with
excess body weight. It also occurs more frequently in non-
weight-bearing joints, suggesting that components of the
obesity syndrome alter cartilage and bone metabolism inde-
pendent of weight bearing. In one study of more than 1000
women, obesity was classified as the upper tertile of BMI; the
middle tertile had a BMI range of 23.4 to 26.4 kg/m2. The
age-adjusted odds ratios of unilateral and bilateral osteoar-
thritis at the knee, determined from x-ray films of the knees
comparing the high and low tertiles of BMI, were 6.2 and 18,
respectively.46 Lesser increases occurred in the odds ratio for
arthritis in various joints, between the middle and lower
tertiles. A twin study found similar results; each kilogram
increase in body weight (compared with a twin control) was
associated with an increased risk of radiographic features of
osteoarthritis at the knee and carpometacarpal joint.47 Weight
loss is associated with a decreased risk of osteoarthritis. In a
study of 800 women a decrease in BMI of 2 kg/m2 in the
preceding 10 years decreased the odds for developing osteo-
arthritis by more than 50%.48 This benefit also was found
among those women with a high risk for osteoarthritis due to
a high baseline BMI (25 kg/m2). Chest pain produced by
mechanical problems in the back because of obesity also is
common.
Cancer
A working group of the International Agency for Research on
Cancer (IARC) of the WHO reviewed the association be-
tween overweight and cancer and concluded that sufficient
evidence exists for a cancer-preventive effect of avoidance of
weight gain (prevention of overweight).49 This evidence has
been obtained for cancers of the colon, breast (in postmeno-
pausal women), endometrium, kidney (renal cell), and esoph-
agus (adenocarcinoma). For premenopausal breast cancer the
available evidence on the avoidance of weight gain suggests
the lack of a cancer-preventive effect.
Fertility
Both infertility and hirsutism are more common in obese than
in nonobese women. In part this is due to the capacity of
adipose tissue to aromatize androgens to estrogens or metab-
olize them to other androgens. Despite this fact, obesity
usually is not associated with alterations in plasma gonado-
trophin (eg, luteinizing hormone, follicle-stimulating hor-
mone) levels or the hypothalamic-pituitary control of these
hormones. Polycystic ovarian syndrome and moderate obe-
sity are frequently associated, and many of the women with
this condition have insulin resistance50 and/or other compo-
nents of the metabolic syndrome. Many women enrolled in in
vitro or assisted fertilization programs are overweight or
obese. A small weight loss will increase both fertility and
success of the program.
Other Disorders
Obesity is associated with a wide range of comorbidities and
these were well covered in the WHO Technical Report.2
Additional metabolic problems include hyperuricemia and
gout, and a direct relationship exists between obesity and
gallbladder disease, which increases with age. Varicose veins
are common because of increased pressure, and lympho-
edema may result. Skin ulcerations and deep venous throm-
bosis are common in persons with grade III obesity (BMI
40). Pulmonary embolism may occur,2 particularly in per-
sons with decreased mobility. Cor pulmonale, sometimes
associated with sleep apnea, also can occur.
In addition to these medical factors, a great many psycho-
social problems are associated with obesity. Obese people
have a reduced quality of life, are more likely to be divorced
(men) or never married (women), to have fewer employment
prospects, and to be stigmatized socially.51–56
Modifying Factors
Fat Distribution and the Metabolic Syndrome
BMI is most widely used as an indicator of overall fatness.
Variation in BMI may reflect variation in lean body mass and
fat mass but not the distribution of fat. The waist circumfer-
ence tends to reflect both total and regional fatness, especially
in the higher age ranges.57 It is commonly accepted that
accumulation of fat in the abdominal region is particularly
related to an increased risk of cardiovascular disease through
its association with the metabolic syndrome. Individuals with
the metabolic syndrome are at increased risk for developing
diabetes mellitus and cardiovascular disease.58 Abdominal
obesity, as measured by a large waist circumference, is part of
the National Cholesterol Education Program Adult Treatment
Panel III definition of the metabolic syndrome. Patients
having 3 or more of the following criteria are defined as
having the metabolic syndrome:
1. Abdominal obesity: waist circumference 102 cm in men
and 88 cm in women.
2. Hypertriglyceridemia: 1.69 mmol/L
3. Low high-density lipoprotein cholesterol: 1.04 mmol/L
in men and 1.29 mmol/L in women
4. High blood pressure: 130/85 mm Hg
5. High fasting glucose: 6.1 mmol/L
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Metabolic syndrome is prevalent in the United States.59
The age-adjusted prevalence was found to be about 24% in
US adults and increased sharply with age.
Waist circumference is closely linked to the amount of
intraabdominal or visceral adipose tissue. The main hypoth-
esis linking visceral adipose tissue accumulation to the
metabolic syndrome, T2DM, and cardiovascular disease is
through hepatic overexposure to fatty acids.60 Visceral fat is
characterized by high lipolytic activity and by drainage by the
portal vein. Alternative or additional explanations exist for a
relationship between fat mass and the metabolic syndrome.
First, adipose tissue is an endocrine organ secreting many
peptides that have been linked to aspects of the metabolic
syndrome.61 These peptides include leptin, resistin, adiponec-
tin, angioteninogen, interleukin-6, TNF-, adipsin, and plas-
minogen activator inhibitor-1.55 Some of these proteins are
inflammatory cytokines, some play a role in lipid metabo-
lism, and others are involved in vascular hemostasis or the
complement system. Second, several hormonal factors may
be underlying factors that are related to both abdominal fat
distribution and dyslipidemia and insulin resistance. Exam-
ples are high androgen levels in women (low levels in men),
increased concentrations of glucocorticoid hormones, low
levels of growth hormone and insulin-like growth factor-1.62
It has been established that in mice the overexpression of
11- hydroxysteroid dehydrogenase type 1 in adipose tissue
leads to increased visceral adipose tissue, hypertension, and
insulin resistance.63 Behavioral factors such as sedentary
lifestyle, smoking, and dietary habits may be related to the
increased accumulation of abdominal fat as well as other
components of the metabolic syndrome.62
Thus, although the exact mechanisms underlying the asso-
ciations remain to be fully elucidated, an increased accumu-
lation of abdominal fat, as reflected by an increased waist
circumference, is an important diagnostic tool in addition to
BMI.
Some investigators have suggested the use of other ratios
(eg, waist-to-hip, waist-to-thigh, sagittal abdominal diam-
eter–to–thigh). The rational for using these ratios is that the
numerator reflects a combination of total and abdominal fat
mass and the denominator reflects overall body size or
regional body tissue mass (peripheral fat or muscle) that must
be accounted for. Because measurement errors may be
compounded in a ratio and because the interpretation of these
ratios in pathophysiological terms in difficult, the public
health applications of these ratios might be limited. Simple
measurements (eg, waist circumference) are more likely to be
useful in public health efforts.57
Age/Aging
The development of the comorbidities of obesity, particularly
those related to cardiovascular disease, strongly interact with
aging and in fact are predominantly middle-age in onset.
Changing body composition, with increasing proportion of fat
with aging, may underlie the associations among obesity,
aging, and many of these cardiovascular comorbidities. With
the increase of obesity at younger ages, features of these
comorbidities are beginning earlier. Adipose tissue is now
recognized as an endocrine organ, and many of the hormones
and cytokines it produces are under intense investigation for
their possible roles as mediators of comorbidities.
Researchers in aging have long recognized that energy
restriction is the single most powerful intervention to slow
aging processes, reduce the diseases associated with aging,
and extend life span. First demonstrated in rodents, the
extraordinary power of energy restriction to mitigate and/or
prevent the diseases associated with aging has been shown to
be true in nonhuman primates.64,65 These effects appear to
depend on the reduction and maintenance of reduced body
fatness. The converse appears to be happening in humans (the
removal of energy restraints that previously played preven-
tive roles) based on much epidemiological data across ethnic,
cultural, and regional groups, and this plays a significant role
in the development of obesity and cardiovascular diseases.
Experimental interventions also have demonstrated that en-
ergy restriction reduces dyslipidemia in primates,65 prevents
T2DM,64 and slows other diseases of aging, including hyper-
tension and some cancers.66 Thus evidence is mounting that
with energy restraint to prevent obesity or to reduce excess
adiposity, the comorbidities of obesity also will be in large
measure prevented.
Region/Ethnicity
Evidence is accumulating that different ethnic groups may be
affected differently or at different BMIs than others. For
example, in Japanese populations, the relative risk of hyper-
tension is 3 at a BMI of 24.9 kg/m2, with the nadir of risk at
a BMI of 22.6. In Chinese populations evidence exists that
diabetes risk starts at a much lower BMI and doubles within
the defined “healthy” range of BMI; the same is true of the
Australian aboriginal population.67 These and other lines of
evidence have led to the suggestion that in Asian populations
the BMI ranges for “action points” may need to be revised,
with a BMI of 25 kg/m2 indicating the need for treatment.68 In
Japan a BMI of 25 kg/m2 is accepted as obesity grade I. The
Working Group on Obesity in China, after a review of 13 data
sets containing 240 000 people and 4 cohort studies with
70 000 subjects, have suggested that a BMI of 24 kg/m2 may
represent overweight in China and obesity is a BMI 28
kg/m2. Obviously differences exist in both the type of
comorbidity and the BMI at which it occurs in Asian and
other populations. It has been suggested that the occurrence
of comorbidities at lower BMIs may be the result of greater
adiposity in Asians, in particular visceral adiposity.68,69 Con-
versely, it has been suggested that Pacific Island populations
may be protected, having greater lean body mass at any
BMI.70,71 These problems need to be studied further.
Gender
The prevalence of obesity is higher in women in most ethnic
groups and is reflected in differences in comorbidities. The
risk of developing diabetes, hypertension, gallbladder dis-
ease, and coronary artery disease differs by ethnic group and
by gender within ethnic group. This is particularly evident for
those with BMI 40 kg/m2 but also is present at BMIs
between 30 and 40 kg/m2. In white women the risk of T2DM
is greater than the risk of hypertension, which in turn is
greater than the risk of gallbladder disease. Although the risk
of diabetes also is high in white men, the risk of gallbladder
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disease exceeded that of hypertension. In African American
and Mexican American men the risk of hypertension was
higher than that of diabetes. In African American women the
risks of diabetes and gallbladder disease were higher, whereas
in Mexican American women risks of CHD, diabetes, and
gallbladder disease were similar, and the odds ratio was less
than in corresponding African American or white women.
These ethnic and gender differences undoubtedly reflect the
interaction of genetic and environmental factors.
Research Directions
Obesity is increasing in prevalence throughout the world.
Obesity is a “risk factor” for cardiovascular disease, and with
its increasing prevalence there are increases in metabolic
disease (particularly T2DM) and many other disorders and
these have been detailed in this chapter.
Important areas for research and intervention include the
following:
1. Long-term longitudinal studies to determine whether
the risks of obesity for cardiovascular disease and
metabolic disease, in particular, are the same across all
populations and ethnic groups; these studies will help
answer whether specific (or lower) action points in
specific populations are needed or whether different
approaches for the prevention of cardiovascular and
metabolic diseases are needed
2. Studies to determine the specific factors that determine
weight (adipose tissue) gain and particularly those
factors that predispose individuals to abdominal
adiposity
3. The development of effective weight maintenance
programs and studies to determine whether they will
reduce cardiovascular (and other disease) morbidity
and mortality
4. The development of strategies for the prevention of
obesity, which may be directed at children and ado-
lescents, at-risk populations, or the population as a
whole; these studies and interventions need to be
applied regionally, assessed rigorously, and those
which are effective applied generally (few effective
population strategies exist, and it must be expected
that not all strategies will be successful)
5. Prevention of obesity in childhood and adolescence
expected to contribute to the prevention of dyslipid-
emia and hypertension; studies at the clinical and then
the population level are needed to evaluate the effec-
tiveness of interventions against obesity on these
further endpoints
6. Studies to determine whether the effectiveness of
weight-loss interventions is greater than the benefits
of controlling comorbidities through medical
management
7. Studies to increase our knowledge of control of fat cell
deposition and its relationship to disease risk
8. Studies to identify the determinants of why certain
individuals do not develop overweight or obesity
9. Studies to help translate improved knowledge into
actual lifestyle modification (behavior change)
10. Studies to assess the relative benefits of weight loss
versus increased physical activity
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